GeoVax Responds to WHO's Fourth Declaration of Mpox as a Global Public Health Emergency
ATLANTA, GA - June 11, 2025 ( NEWMEDIAWIRE ) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies, today issued a statement in response to the World Health Organization's (WHO) fourth declaration of Mpox as a Public Health Emergency of International Concern (PHEIC). The WHO's decision reflects the ongoing global spread of the highly virulent Clade 1 strain of the Mpox virus, which has prompted heightened international concern and a call to action for more robust vaccine strategies.
Mpox continues to pose a significant threat to global health, with WHO reporting rising case counts in endemic and non-endemic regions alike. In particular, Clade 1 Mpox - previously confined to Central Africa - is now appearing in Europe, Asia, and North America. In the United States, multiple confirmed Clade 1 cases have been reported across New York, California, Georgia, and New Hampshire. Additionally, Clade 1 viral particles have been detected in wastewater in North Carolina, California, Alabama and Iowa, suggesting silent transmission may be occurring even before symptomatic cases emerge.
U.S. and Global Reliance on a Single Supplier Threatens Response Capacity
Despite the urgency, the world remains dangerously dependent on a single manufacturer for the preferred Mpox vaccine, based on the Modified Vaccinia Ankara (MVA) platform. This presents significant risks to biosecurity, affordability, and equitable distribution. African nations alone have requested 20 million doses for 2025; global capacity is estimated at only 2–5 million doses annually.
GEO-MVA: America's Strategic Vaccine Alternative
GeoVax is actively developing GEO-MVA, a U.S.-based MVA vaccine for Mpox and smallpox. GEO-MVA is engineered as an alternative to the existing global supply and has been recognized at global forums as a pivotal component of future pandemic resilience.
GeoVax has completed cGMP drug substance manufacturing of GEO-MVA, with fill/finish processes underway. Clinical vials are expected to be available in Q4 '25, enabling clinical trials to begin in 2026.
GEO-MVA is also being developed using an advanced continuous avian cell line manufacturing process, intended to:
'WHO's latest declaration underscores that the Mpox crisis is not behind us - it is escalating,' said David Dodd, Chairman & CEO of GeoVax. 'As Clade 1 spreads in the U.S. and globally, we must act now to expand domestic vaccine capacity. Single-source dependency threatens access during geopolitical or logistical disruptions. GEO-MVA offers a scalable, cost-effective, and onshore alternative that supports national security, global equity, and pandemic preparedness.'
Strengthening Biosecurity and Public Health Readiness
GeoVax is engaged with U.S. federal agencies to align GEO-MVA with government initiatives aimed at onshoring critical pharmaceutical manufacturing and strengthening national pandemic readiness. The company's proposal under BARDA's Rapid Response Partnership Vehicle (RRPV) was selected for award, pending funding, to scale MVA-based vaccine production using advanced U.S. biomanufacturing technologies.
GeoVax is calling on global and national policymakers to:
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin(R), having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. The Company is also developing GEO-MVA, a vaccine targeting Mpox and smallpox. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.
Forward-Looking Statements
This release contains forward-looking statements regarding GeoVax's business plans. The words 'believe,' 'look forward to,' 'may,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'should,' 'plan,' 'could,' 'target,' 'potential,' 'is likely,' 'will,' 'expect' and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax's immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax's viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax's immuno-oncology products and preventative vaccines will be safe for human use, GeoVax's vaccines will effectively prevent targeted infections in humans, GeoVax's immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.Company Contact:
[email protected]
678-384-7220
Investor Relations Contact:
[email protected]
212-698-8696
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fast Company
43 minutes ago
- Fast Company
Heartflow stock listing and IPO date draw near: AI-powered medtech aims for $1.3 billion valuation
It seems there's fresh blood pumping back into the IPO market. After a blowout initial public offering from Figma last week, investors might have another chance to get their heart rates up again soon. Heartflow, a California-based medtech company that utilizes AI with imaging and diagnostics software to help evaluate cardiac and coronary diseases, is looking to list shares on the Nasdaq. In paperwork filed on Friday with the Securities and Exchange Commission (SEC), Heartflow said it plans to offer 12.5 million shares, priced between $15 and $17. That could potentially raise more than $208 million. According to Reuters, Heartflow's target valuation could be as high as $1.3 billion. The company plans to trade under the ticker 'HTFL.' Subscribe to the Daily newsletter. Fast Company's trending stories delivered to you every day Privacy Policy | Fast Company Newsletters Personalized 3D-models of people's hearts Heartflow uses AI and other technology to scan patients for coronary and cardiac problems, creating three-dimensional models of patients' hearts. The Food and Drug Administration (FDA) gave the software the green light in 2022, and it's now being used in some markets to diagnose patients. Additionally, the company got a leg up last year when the U.S. Centers for Medicare and Medicaid Services (CMS) expanded Medicare coverage to include platforms that use imaging results to look for signs of coronary disease, and the American Medical Association (AMA) issued a new Category I CPT code for those platforms. That gives doctors and clinics the go-ahead to start using the technology on a broader scale starting next year. According to the company's SEC filing, Heartflow says that as of the end of March 2025, it's been used to assess more than 400,000 patients. Revenues are growing but profits are elusive Heartflow generated $125.8 million in 2024, a 44% increase over the $87.2 million it made the year before, the company says. Revenue likewise grew 39% for the first quarter of 2025 to $37.2 million. However, the company saw a net loss of $96.4 million in 2024, wider than its net loss of $95.7 million in 2023. It warns in the filing that it expects to incur 'substantial losses in the foreseeable future [and] may not be able to achieve or sustain profitability.' Bain Capital, Panorama Point Partners, and Capricorn Investment Group are among Heartflow's backers, according to Crunchbase. Bain led its most recent fundraising round, a Series F round in 2023, which raised $215 million. This is not the first time that Heartflow has attempted to go public. The company had planned to merge with a special purpose acquisition company during the SPAC frenzy of the early pandemic years, but it halted the plan in 2022, citing 'unfavorable market conditions,' as Fierce Biotech reported. Heartflow's IPO comes on the heels of another growing medtech company's public debut. Carlsmed, which specializes in AI-driven spine surgery technology, recently went public as well, with shares trading on July 23. Since then, the stock is down around 4.5%. Heartflow has not said when it plans to list its stock. Fast Company reached out for more details on the timeline and will update this post if we hear back.
San Francisco Chronicle
an hour ago
- San Francisco Chronicle
What to know about Legionnaires' disease, which has sickened dozens in New York City
An outbreak of Legionnaires' disease in New York City has killed two people and sickened 58 since late July. City health officials link the Central Harlem outbreak to cooling towers, structures containing water and a fan that are used to cool buildings. They said 11 of these towers initially tested positive for a type of bacteria that causes Legionnaires' disease, but the problem has been remedied. They urged people in the area with flu-like symptoms to contact a health care provider as soon as possible, especially if they are 50 or older, smoke or have chronic lung conditions. Here's what to know. What is Legionnaires' disease? It's a type of pneumonia caused by Legionella bacteria, which grow in warm water and spread in building water systems. They can be found in places such as showerheads, hot tubs and cooling towers. People often get the disease by inhaling aerosols from contaminated water. Hospital patients can also contract it through contaminated water or ice, and babies can be exposed during water births, health officials said. People don't get it from each other. Symptoms usually develop two days to two weeks after exposure and include cough, fever, headaches, muscle aches and shortness of breath, according to the U.S. Centers for Disease Control and Prevention. How does Legionnaires' disease hurt you and how can you treat it? It's important to be diagnosed quickly and treated with the appropriate antibiotics, health officials said. If untreated, the disease usually worsens during the first week, the World Health Organization said. Complications can include respiratory failure, shock and kidney or multi-organ failure. How can Legionnaires' disease be prevented? People responsible for the safety of buildings and water systems can reduce the threat by taking steps to minimize the growth of the bacteria, the WHO said. For example, they should regularly clean and disinfect cooling towers, maintain an adequate level of chlorine in spa pools and flush unused taps in buildings weekly. There are also steps people can take to reduce the risk of Legionnaires' disease at home. New York state health officials suggest draining garden hoses; following manufacturers' instructions for cleaning and replacing water filters; checking chlorine levels in pools and hot tubs regularly and flushing hot water heaters twice a year. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Yahoo
4 hours ago
- Yahoo
Alcon Expands Vision Correction Portfolio With STAAR Surgical Acquisition
On Tuesday, the eye care company Alcon Plc (NYSE:ALC) agreed to acquire STAAR Surgical Company (NASDAQ:STAA), the manufacturer of the implantable collamer lens (ICL). The acquisition includes the EVO family of lenses (EVO ICL) for vision correction for patients with moderate to high myopia (nearsightedness), with or without astigmatism. Alcon will purchase all outstanding shares of STAAR common stock for $28 per share in cash, which represents approximately a 59% premium to STAAR's 90-day Volume Weighted Average Price (VWAP) and a 51% premium to the closing price of STAAR common stock on August 4, transaction represents a total equity value of approximately $1.5 billion. Alcon intends to finance the transaction by issuing short- and long-term credit facilities. The transaction is anticipated to close in approximately six to 12 months and is expected to be accretive to earnings in year two. 'With the number of high myopes rising globally, the acquisition of STAAR enhances our ability to offer a leading surgical vision correction solution for those who are not ideal candidates for other refractive surgeries such as LASIK,' said David Endicott, CEO of Alcon. An estimated 50% of the world will be myopic by 2050, and today, nearly 500 million people are considered high myopes. The EVO family of ICLs are implanted between the iris (the colored part of the eye) and the natural crystalline lens during a procedure that does not remove corneal tissue. This move follows Alcon's recent announcement in July regarding its intention to acquire LumiThera, Inc. and its Photobiomodulation (PBM) Device for dry age-related macular degeneration (AMD). Data from the LIGHTSITE I, II, and III clinical trials consistently showed that PBM treatments provide visual acuity improvement with no treatment-related serious adverse events reported. PBM received FDA de novo market authorization in November 2024 and CE Mark in November 2018. PBM is available in Europe, Latin America, Singapore, the U.K., and the U.S. The transaction does not include the acquisition of AdaptDx and Nova/Diopsys diagnostic devices, which will be separated and spun off to LumiThera's shareholders before Alcon's acquisition and will continue to be marketed and sold by the LumiThera spin-off. Alcon and LumiThera anticipate the acquisition to be completed in the third quarter of 2025. Price Action: ALC stock is trading lower by 1.17% to $86.79 premarket, and STAA stock is trading higher by 44.9% to $26.78 at last check Tuesday. Read Next:Photo via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? STAAR SURGICAL (STAA): Free Stock Analysis Report This article Alcon Expands Vision Correction Portfolio With STAAR Surgical Acquisition originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
